A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients

被引：0

作者：

Tsirigotis, Panagiotis ^{[1
]}

Bitan, Reuven Or Menachem ^{[1
]}

Resnick, Igor B. ^{[1
]}

Samuel, Simcha ^{[1
]}

Ackerstein, Aliza ^{[1
]}

Elad, Sharon ^{[1
]}

Gesundheit, Benjamin ^{[1
]}

Zilberman, Irina ^{[1
]}

Miron, Svetlana ^{[1
]}

Leubovic, Alexander ^{[1
]}

Slavin, Shimon ^{[1
]}

Shapira, Michael Y. ^{[1
]}

机构：

[1] Hebrew Univ Jerusalem, Dept Bone Marrow Transplantat & Canc Immunotherap, Hadassah, Med Ctr, POB 12000, IL-91120 Jerusalem, Israel

来源：

HAEMATOLOGICA | 2006年 / 91卷 / 06期

关键词：

allogeneic bone marrow transplantation; graft-versus-host disease; immunotherapy; elderly; co-morbidity;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We describe our experience with the use of a single non-myeloablative preparative regimen in stem cell transplantation (NST) in 37 heavily pretreated patients >= 55 years. The conditioning regimen consisted of fludarabine, low-dose busulfan, and antithymocyte globulin. Acute graft-versus-host disease (GVHD) grade III-IV and chronic GVHD developed in 15.6% and 44.4% of cases, respectively. With a median follow-up period of 22 (range 3-113) months, the 1-year overall survival and disease-free-survival rates were 55% and 53%, respectively, while the overall non-relapse mortality was 35%. In conclusion, reduced intensity stem cell transplantation is feasible and effective in patients >= 55 years. Age per se, should no longer be considered as a contra-indication to stem cell transplantation.

引用

页码：852 / 855

页数：4

共 14 条

[1] Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia [J].

Bertz, H ;

Potthoff, K ;

Finke, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1480-1484

[2] Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years [J].

Cahn, JY ;

Labopin, M ;

Schattenberg, A ;

Reiffers, J ;

Willemze, R ;

Zittoun, R ;

Bacigalupo, A ;

Prentice, G ;

Gluckman, E ;

Herve, P ;

Gratwohl, A ;

Gorin, NC .

LEUKEMIA, 1997, 11 (03) :416-419

[3] Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation [J].

Giralt, S ;

Thall, PF ;

Khouri, I ;

Wang, XM ;

Braunschweig, I ;

Ippolitti, C ;

Claxton, D ;

Donato, M ;

Bruton, J ;

Cohen, A ;

Davis, M ;

Andersson, BS ;

Anderlini, P ;

Gajewski, J ;

Kornblau, S ;

Andreeff, M ;

Przepiorka, D ;

Ueno, NT ;

Molldrem, J ;

Champlin, R .

BLOOD, 2001, 97 (03) :631-637

[4] Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older [J].

Gupta, V ;

Daly, A ;

Lipton, JH ;

Hasegawa, W ;

Chun, C ;

Kamel-Reid, S ;

Tsang, R ;

Yi, QL ;

Minden, M ;

Messner, H ;

Kiss, T .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (10) :764-772

[5] Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies [J].

Hamaki, T ;

Kami, M ;

Kim, SW ;

Onishi, Y ;

Kishi, Y ;

Murashige, N ;

Hori, A ;

Kojima, R ;

Sakiyama, M ;

Imataki, O ;

Heike, Y ;

Tanosaki, R ;

Masuo, S ;

Miyakoshi, S ;

Taniguchi, S ;

Tobinai, K ;

Takaue, Y .

BONE MARROW TRANSPLANTATION, 2004, 33 (09) :891-900

[6]

Molina AJ, 2000, HDB BONE MARROW TRAN, P111

[7] Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases [J].

Niederwieser, D ;

Maris, M ;

Shizuru, JA ;

Petersdorf, E ;

Hegenbart, U ;

Sandmaier, BM ;

Maloney, DG ;

Storer, B ;

Lange, T ;

Chauncey, T ;

Deininger, M ;

Pönisch, W ;

Anasetti, C ;

Woolfrey, A ;

Little, MT ;

Blume, KG ;

McSweeney, PA ;

Storb, RF .

BLOOD, 2003, 101 (04) :1620-1629

[8] Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia:: disease status by marrow blasts is the strongest prognostic factor [J].

Sayer, HG ;

Kröger, M ;

Beyer, J ;

Kiehl, M ;

Klein, SA ;

Schaefer-Eckart, K ;

Schwerdtfeger, R ;

Siegert, W ;

Runde, V ;

Theuser, C ;

Martin, H ;

Schetelig, J ;

Beelen, DW ;

Fauser, A ;

Kienast, J ;

Höffken, K ;

Ehninger, G ;

Bornhäuser, M .

BONE MARROW TRANSPLANTATION, 2003, 31 (12) :1089-1095

[9] Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients [J].

Shapira, MY ;

Resnick, IB ;

Bitan, M ;

Ackerstein, A ;

Samuel, S ;

Elad, S ;

Miron, S ;

Zilberman, I ;

Slavin, S ;

Or, R .

BONE MARROW TRANSPLANTATION, 2004, 34 (02) :155-159

[10] Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age > 55 years) with hematologic malignancies:: older age is no longer a contraindication when using reduced intensity conditioning [J].

Shimoni, A ;

Kröger, N ;

Zabelina, T ;

Ayuk, F ;

Hardan, I ;

Yeshurun, M ;

Shem-Tov, N ;

Avigdor, A ;

Ben-Bassat, I ;

Zander, AR ;

Nagler, A .

LEUKEMIA, 2005, 19 (01) :7-12

← 1 2 →